University of North Carolina Gillings School of Global Public Health, Department of Health Behavior and Health Education, Chapel Hill, North Carolina 27599-7440, USA.
Sex Transm Infect. 2010 Jun;86(3):241-6. doi: 10.1136/sti.2009.039065. Epub 2009 Nov 30.
If approved for use in young males in the United States, prophylactic human papillomavirus (HPV) vaccine may reduce the incidence of HPV-related disease in vaccinated males and their sexual partners. We aimed to characterise heterosexual men's willingness to get HPV vaccine and identify correlates of vaccine acceptability.
Participants were from a national sample of heterosexual men (n=297) aged 18-59 y from the United States who were interviewed in January 2009. We analysed data using multivariate logistic regression.
Most men had not heard of HPV prior to the study or had low HPV knowledge (81%; 239/296). Most men had heard of HPV vaccine prior to the study (63%; 186/296) and 37% (109/296) were willing to get HPV vaccine. Men were more willing to get vaccinated if they reported higher perceived likelihood of getting HPV-related disease (OR 1.80, 95% CI 1.02 to 3.17), perceived HPV vaccine effectiveness (OR 1.86, 95% CI 1.22 to 2.83) or anticipated regret if they did not get vaccinated and an HPV infection later developed (OR 2.01, 95% CI 1.40 to 2.89). Acceptability was also higher among men who thought (OR 9.02, 95% CI 3.45 to 23.60) or who were unsure (OR 2.67, 95% CI 1.30 to 5.47) if their doctor would recommend they get HPV vaccine if licensed for males.
Men had low HPV knowledge and were moderately willing to get HPV vaccine. These findings underscore the need for HPV educational efforts for men and provide insight into some of the factors that may affect the HPV vaccination decision making process among men.
如果在美国获准用于年轻男性,预防性人乳头瘤病毒(HPV)疫苗可能会降低接种疫苗的男性及其性伴侣中 HPV 相关疾病的发病率。我们旨在描述异性恋男性接种 HPV 疫苗的意愿,并确定疫苗可接受性的相关因素。
参与者来自美国的全国异性恋男性样本(n=297),年龄在 18-59 岁,于 2009 年 1 月接受采访。我们使用多变量逻辑回归分析数据。
大多数男性在研究之前没有听说过人乳头瘤病毒或对 HPV 知识了解甚少(81%;239/296)。大多数男性在研究之前听说过 HPV 疫苗(63%;186/296),37%(109/296)愿意接种 HPV 疫苗。如果男性报告 HPV 相关疾病的发病几率较高(OR 1.80,95%CI 1.02 至 3.17)、HPV 疫苗的有效性(OR 1.86,95%CI 1.22 至 2.83),或如果他们没有接种疫苗且之后感染了 HPV ,他们会感到遗憾(OR 2.01,95%CI 1.40 至 2.89),则更愿意接种疫苗。如果男性认为(OR 9.02,95%CI 3.45 至 23.60)或不确定(OR 2.67,95%CI 1.30 至 5.47)他们的医生是否会推荐他们接种 HPV 疫苗,如果疫苗获准用于男性,则可接受性也会更高。
男性对 HPV 的了解较少,对 HPV 疫苗的接种意愿也适中。这些发现强调了对男性进行 HPV 教育的必要性,并提供了一些可能影响男性 HPV 疫苗接种决策过程的因素的见解。